New JP Draft 2.28 Circular Dichroism Spectroscopy Published for Public Comments
Recommendation

Thursday, 3 September 2026 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has published a Japanese Pharmacopoeia (JP) draft of a New General Test 2.28 Circular Dichroism Spectroscopy.
The chapter starts with a short introduction to the topic and an explanation of the relevant equations and definitions. The method is defined as follows:
The circular dichroism spectroscopy is a method used to analyze and determine the structure of optically active substances, discriminate active substances from enantiomers, diastereomers, etc by using the phenomenon (circular dichroism) in which the degrees of absorption of left and right circularly polarized lights differ in the absorption wave length region of active substances.
After the general introduction, the new chapter is divided into the following chapters and subchapters:
- 1. Apparatus
- 2. Methods
2.1. Identification test
2.2. Analysis of secondary structure - 3. Verification of the performance of apparatus
3.1. Accuracy of circular dichroism
3.2. Linearity of modulation
The draft document is available as a PDF file on the PMDA's website. Comments can be submitted until September 30, 2021. For this purpose, a form for comments has to be downloaded and sent by e-mail after it has been filled in.
Related GMP News
01.07.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products
24.06.2026Analytical Quality Group Developments January through April 2026
17.06.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation


